A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation

Trial Profile

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs GLPG 2222 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Acronyms ALBATROSS
  • Sponsors Galapagos NV
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Nov 2017 This trial has been completed in Germany (end date: 2017-08-11).
    • 20 Nov 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top